SINOVAC BIOTECH LTD. - Common Shares (SVA)

Historical Holders from Q1 2014 to Q3 2025

Symbol
SVA on Nasdaq
Type / Class
Equity / Common Shares
Shares outstanding
71,858,757
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
8,982,045
Holdings value
$224,989,943
% of all portfolios
0%
Number of holders
8
Number of buys
3
Number of sells
-1
Average buys %
0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SINOVAC BIOTECH LTD. - Common Shares (SVA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
1Globe Capital LLC 32.3% 0% 18,515,315 0% 1Globe Capital LLC 07 Jul 2025
SAIF Partners IV L.P. 15% 0% 10,780,820 0% SAIF Partners IV L.P. 10 Jul 2025
WEIDONG YIN 8.85% 0% 6,359,500 0% Weidong Yin 10 Jul 2025
Advantech Capital L.P. 8.14% 0% 5,851,423 0% Advantech Capital L.P. 08 Jul 2025
Vivo Capital VIII, LLC 6.3% 0% 4,541,764 0% Vivo Capital IX, LLC 11 Jul 2025
Vivo Capital IX, LLC 6.3% $293,522,587 4,539,456 Vivo Capital IX, LLC 17 Mar 2025

Institutional Holders of SINOVAC BIOTECH LTD. - Common Shares (SVA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 8,982,045 $224,989,943 -$843,805 $6.47 8
2025 Q2 10,293,731 $375,364,173 +$39,325,578 $6.47 9
2025 Q1 3,034,321 $336,038,595 $64.66 2
2024 Q4 3,034,321 $336,038,595 -$76,346,336 $64.66 2
2024 Q3 14,834,373 $418,388,336 -$1,189,079 $6.47 4
2024 Q2 13,494,548 $79,577,415 -$1,059,870 $6.47 10
2024 Q1 12,345,841 $79,877,748 +$74,637,726 $6.47 11
2023 Q4 3,035,348 $345,241,022 -$39,640,820 $125.06 5
2023 Q3 6,591,632 $41,683,415 -$241,827 $6.47 14
2023 Q2 654,395 $4,040,321 +$1,998,321 $6.47 13
2023 Q1 8,934,321 $957,411,410 $104.3 3
2022 Q4 6,846,776 $44,307,000 -$2,179,000 $6.47 5
2022 Q3 6,549,095 $42,402,000 -$54,272 $6.47 15
2022 Q2 6,556,811 $43,219,000 +$1,612,000 $6.48 15
2022 Q1 6,307,855 $41,615,000 -$2,526,064 $6.47 6
2021 Q4 6,703,614 $43,337,796 +$45,098 $6.47 14
2021 Q3 6,692,031 $43,303,000 -$2,609 $6.47 14
2021 Q2 17,473,080 $448,658,000 -$10,419 $6.47 15
2021 Q1 6,694,343 $43,301,798 +$795,406 $6.47 14
2020 Q4 19,723,128 $113,774,000 -$4,542 $6.47 14
2020 Q3 6,567,108 $42,490,000 -$12,370 $6.47 13
2020 Q2 6,569,021 $42,502,000 -$443,106 $6.47 13
2020 Q1 9,476,962 $60,096,177 +$37,810,000 $6.47 16
2019 Q4 3,626,233 $22,285,000 +$420,812 $6.47 16
2019 Q3 5,943,883 $36,697,000 -$37,950,207 $6.47 14
2019 Q2 11,809,394 $74,647,000 -$363,749 $6.47 16
2019 Q1 11,866,163 $76,776,000 -$565,886 $6.47 20
2018 Q4 12,055,479 $83,665,328 -$1,526,233 $6.94 27
2018 Q3 12,261,649 $93,426,144 +$44,029,531 $7.62 27
2018 Q2 6,485,621 $48,379,952 -$2,603,545 $7.46 27
2018 Q1 6,825,579 $58,765,332 -$771,809 $8.61 27
2017 Q4 7,195,807 $56,704,456 -$4,237,018 $7.88 30
2017 Q3 18,130,684 $127,807,000 +$4,504,862 $7.04 34
2017 Q2 17,497,550 $118,106,000 -$9,432,662 $6.75 37
2017 Q1 18,903,143 $108,310,000 -$16,467,400 $5.73 35
2016 Q4 21,710,524 $128,091,000 -$2,317,439 $5.9 36
2016 Q3 11,345,665 $66,941,000 -$3,525,877 $5.9 36
2016 Q2 11,940,291 $70,803,000 -$984,267 $5.93 36
2016 Q1 12,095,339 $77,284,000 -$2,891,830 $6.39 34
2015 Q4 12,667,219 $72,454,000 -$2,035,397 $5.72 36
2015 Q3 13,170,988 $67,305,000 +$3,241,877 $5.08 34
2015 Q2 12,671,847 $66,523,675 +$330,944 $5.25 33
2015 Q1 12,615,535 $62,556,816 -$1,441,431 $4.96 37
2014 Q4 12,882,608 $67,344,058 -$771,710 $5.23 42
2014 Q3 12,951,642 $62,291,531 -$3,158,978 $4.81 43
2014 Q2 13,183,464 $74,347,660 -$7,915,266 $5.64 50
2014 Q1 14,476,121 $104,126,600 +$13,345,733 $7.2 51